Maravai LifeSciences
MRVI
220 hedge funds and large institutions have $1.79B invested in Maravai LifeSciences in 2023 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 91 increasing their positions, 60 reducing their positions, and 31 closing their positions.
52% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 60
35% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 31
4% more funds holding
Funds holding: 212 → 220 (+8)
1.2% more ownership
Funds ownership: 96.05% → 97.24% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less capital invested
Capital invested by funds: $1.81B → $1.79B (-$14.8M)
16% less call options, than puts
Call options by funds: $1.04M | Put options by funds: $1.24M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1WCM
12 West Capital Management
New York
|
+$36.9M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$28.9M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$19.9M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.6M |
| 5 |
MIIM
Mesirow Institutional Investment Management
Chicago,
Illinois
|
+$11.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$37.1M |
| 2 |
Select Equity Group
New York
|
-$36.1M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$25.4M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$18.5M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$15.1M |
MRVI Hedge Fund Activity: Q1 2023 in Review
220 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q1 2023, worth a combined $1.79B — down 0.82% from $1.81B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new MRVI positions and 31 closed out — a net gain of 11 holders — while 91 added to existing stakes and 60 trimmed.
The largest buyer was 12 West Capital Management, opening a new position worth an estimated $36.9M. The largest seller was Millennium Management, cutting an estimated $37.1M.
- 220 institutional investors held Maravai LifeSciences (MRVI) as of Q1 2023, up from 212 in Q4 2022.
- Funds reported $1.79B of Maravai LifeSciences stock for Q1 2023, down 0.82% quarter-over-quarter.
- 42 funds opened new Maravai LifeSciences positions in Q1 2023 and 31 closed out, a net change of +11 holders.
- The largest Maravai LifeSciences buyer in Q1 2023 was 12 West Capital Management, an estimated $36.9M added.
- The largest Maravai LifeSciences seller in Q1 2023 was Millennium Management, an estimated $37.1M sold.
Based on aggregated 13F filings for Q1 2023.